Gilead Sciences, Inc.

Gilead Pharmasset LLC

Virobay, Inc.

Axys Pharmaceuticals, Inc.

Aventis Pharmaceuticals Inc.

Schering Aktiengesellschaft

Syntex (u.s.a.) Inc.

Aventis Pharma S.a.

Quest Diagnostics Investments, Inc.

John O Link

Jeromy J Cottell

James G Taylor

Darryl Kato

Elizabeth M Bacon

Scott D Schroeder

Zheng-Yu Yang

Sheila M Zipfel

Winston C Tse

Teresa Alejandra Trejo Martin

William John Watkins

Michael Graupe

Ashley Anne Katana

Hyung-Jung Pyun

Jennifer R Zhang

Randall W Vivian

Evan S Krygowski

Randall Halcomb

Thorsten A Kirschberg

Qi Liu

Eda Y Canales

Chinh Viet Tran

Aesop Cho

Scott E Lazerwith

Michael L Mitchell

Chien-Hung Chou

Choung U Kim

Lianhong Xu

Hongtao Liu

Hongyan Guo

Elbert Chin

Jay P Parrish

Nathan E Wright

Jianyu Sun

Steven S Bondy

Kirk L Stevens

Roland D Saito

Yunfeng Eric Hu

Jeff A Zablocki

Richard L Mackman

Gary Bruce Phillips

Manoj C Desai

Jiayao Li

Carina E Cannizzaro

Musong Kim

Adam James Schrier

Neil H Squires

Nathan D Shapiro

Gayatri Balan

Michael Sangi

Qiaoyin Wu

Julie Farand

Soon Hyung Woo

Gediminas J Brizgys

Chienhung Chou

Christopher T Clark

Kapil Kumar Karki

Chandrasekar Venkataramani

Dustin S Siegel

Barton W Phillips

Tetsuya Kobayashi

John W Patterson

Michael O'Neil Hanrahan Clarke

Ruben Martinez

Kerim Babaoglu

Kevin S Currie

Adrian S Ray

Cheng Yong Yang

Dimitrios Stefanidis

Paul A Roethle

Zhimin Du

Ryan McFadden

Jie Liu

Paul Hrvatin

Scott A Mitchell

Peter A Blomgren

Jeffrey E Kropf

Jianjun Xu

Gregory Notte

Seung H Lee

Juan A Guerrero

Zhongdong Zhao

Aaron C Schmitt

Jayaraman Chandrasekhar

Jennifer R Lo

David John Aldous

Hong Yang

In Jong Kim

Frank Halley

Haolun Jin

Oliver L Saunders

Samuel E Metobo

Michael R Mish

Jie Xu

James T Palmer

John J Nestor, Jr

Hang Chu

Evangelos Aktoudianakis

Gary A Peltz

Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I): Wherein the variable substituents are described herein.

Tetracyclic compounds and methods for the treatment of Zika virus infection

The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

HIV inhibitor compounds

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Therapeutic compounds for HIV virus infection

Therapeutics compounds for HIV virus infection

The invention provides a compound of Formula I:

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

Capsid inhibitors for the treatment of HIV

Provided herein are compounds of Formula (I):

Pentacyclic derivatives as Zika virus inhibitors

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Therapeutic compounds

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

The present disclosure provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject using these compounds. The present disclosure also provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject using these compounds.

HIV protease inhibitors

Growing community of inventors

San Francisco, CA, United States of America

John O Link